At Servier our medicines fit into 4 therapeutic areas: cardiovascular disease, oncology, neuropsychiatric disorders, as well as internal medicine diseases such as diabetes.
Our medicines are prescribed in over 140 countries worldwide. Because a drug may be marketed with different brand names in different countries, most often for legal and cultural reasons, we invite you to visit our subsidiary websites to find out what Servier products are available where you are. As the pages listing available products may be under construction, please visit our website regularly to get the most up-to-date information.
An originator medicinal product, known in some languages by its Latin name, princeps, is a medicine made from an active ingredient that is being used for the first time. This active ingredient has been isolated or synthesised by a pharmaceutical company who then obtains a Marketing Authorization (MA) to sell this specific product.
In essence, it is a patent-protected “original” medicine.
Patents are titles issued by the State through the French National Institute of Industrial Property (Institut National de la Protection Industrielle – INPI). They ensure that the declared creator of an industrial invention (who submits the patent application and supporting evidence) has exclusive rights to utilise the invention for a specified period of time (generally 20 years).
It takes about ten years of Research and Development (2 years to develop new molecular entities, 3 years for preclinical trials, 5 years for clinical trials on humans) to develop an originator product, and frequently 2 more years to wade through the pertinent administrative procedures.
Consequently, when a medicinal product is finally launched on the market, the pharmaceutical company has a maximum of ten years remaining before the original medicine”falls” into the public domain.
The cost of a medicine must therefore allow for the often very expensive investments made at each stage of the creation process.
This is even more remarkable considering that only one in a million molecular entities make it through research and all other subsequent stages to finally become an “original” medicine available to patients.